The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Nov 2011 15:30

RNS Number : 8073R
Byotrol PLC
09 November 2011
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Byotrol Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Ruffer LLP (for its discretionary clients)

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

09 November

6. Date on which issuer notified:

09 November

7. Threshold(s) that is/are crossed orreached: vi, vii

26% to 27%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

 

GB00B0999995

29,690,382

29,690,382

39,957,048

39,957,048

-

27

-

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

39,957,048

27%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

Ruffer LLP controls the voting rights over 39,957,048 shares (27% of the voting rights) of Byotrol Plc.

 

The change in percentage voting rights is due to Ruffer LLP buying 10,266,666 new ordinary shares on behalf of its clients in Byotrol Plc's placing. As a result of the placing, our percentage voting rights increased from 26% to 27%.

14. Contact name:

Louise Stanway

15. Contact telephone number:

020 7963 8146

 

 

 

 

 

 

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Ruffer LLP

Contact address

(registered office for legal entities)

 

80 Victoria Street

London SW1E 5JL

Phone number & email

 

020 7963 8146

lstanway@ruffer.co.uk

Other useful information

(at least legal representative for legal persons)

 

Louise Stanway, Compliance Officer

B: Identity of the notifier, if applicable

Full name

 

Ruffer LLP

Contact address

 

80 Victoria Street

London SW1E 5JL

Phone number & email

 

020 7963 8146

lstanway@ruffer.co.uk

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

Louise Stanway, Compliance Officer

C: Additional information

Ruffer LLP controls the voting rights over 39,957,048 shares (27% of the voting rights) of Byotrol Plc.

 

The change in percentage voting rights is due to Ruffer LLP buying 10,266,666 new ordinary shares on behalf of its clients in Byotrol Plc's placing. As a result of the placing, our percentage voting rights increased from 26% to 27%.

For notes on how to complete form TR-1 please see the FSA website.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLDKCDBPBDDFDK
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.